公开(公告)号：US20120189618A1

公开(公告)日：2012-07-26

申请号：US13182471

申请日：2011-07-14

申请人： Stephan Stilgenbauer ,  Thorsten Zenz ,  Karl-Heinz Heider

发明人： Stephan Stilgenbauer ,  Thorsten Zenz ,  Karl-Heinz Heider

IPC分类号： A61K39/395 ,  A61P35/02 ,  C12N5/071 ,  A61P35/00

CPC分类号： C07K16/2896 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92

摘要： The present invention describes CD37 antibodies, especially A2 and B2, for the treatment of patients with CLL, especially of patients belonging to a “high risk” or “ultra-high risk” group of patients. Those patients are either patients who are refractory to fludarabine treatment or patients who carry a genetic marker which is indicative for poor prognosis or increased risk of treatment failure, e.g. patients with TP53 dysfunction or deletion of chromosome 17p13, or patients after failure to previous anti-CD20 treatment. The ability of A2 and B2 to deplete CLL cells is high both in patient samples derived from patients with normal risk and with increased risk (“high risk” patients) and clearly superior to that of rituximab and alemtuzumab.

摘要翻译： 本发明描述了用于治疗CLL患者，特别是属于“高风险”或“超高危”患者的患者的CD37抗体，特别是A2和B2。 那些患者是氟达拉滨治疗难治的患者或携带遗传标记的患者，其指示预后不良或治疗失败风险增加，例如， 患有TP53功能障碍或缺失染色体17p13的患者，或患者在以前的抗CD20治疗失败后。 来自患有正常风险和风险增加（“高风险”）患者的患者样本中A2和B2消耗CLL细胞的能力高，明显优于利妥昔单抗和阿仑单抗。

公开(公告)号：US20130236454A1

公开(公告)日：2013-09-12

申请号：US13871345

申请日：2013-04-26

申请人： Stephan STILGENBAUER ,  Thorsten ZENZ ,  Karl-Heinz HEIDER

发明人： Stephan STILGENBAUER ,  Thorsten ZENZ ,  Karl-Heinz HEIDER

IPC分类号： A61K39/395

CPC分类号： C07K16/2896 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92

摘要： The present invention describes CD37 antibodies, especially A2 and B2, for the treatment of patients with CLL, especially of patients belonging to a “high risk” or “ultra-high risk” group of patients. Those patients are either patients who are refractory to fludarabine treatment or patients who carry a genetic marker which is indicative for poor prognosis or increased risk of treatment failure, e.g. patients with TP53 dysfunction or deletion of chromosome 17p13, or patients after failure to previous anti-CD20 treatment. The ability of A2 and B2 to deplete CLL cells is high both in patient samples derived from patients with normal risk and with increased risk (“high risk” patients) and clearly superior to that of rituximab and alemtuzumab.

摘要翻译： 本发明描述了用于治疗CLL患者，特别是属于“高风险”或“超高危”患者的患者的CD37抗体，特别是A2和B2。 那些患者是氟达拉滨治疗难治的患者或携带遗传标记的患者，其指示预后不良或治疗失败风险增加，例如， 患有TP53功能障碍或缺失染色体17p13的患者，或患者在以前的抗CD20治疗失败后。 来自患有正常风险和风险增加（“高风险”）患者的患者样本中A2和B2消耗CLL细胞的能力高，明显优于利妥昔单抗和阿仑单抗。